John G Ullman & Associates Inc. Sells 25,233 Shares of Becton, Dickinson and Company $BDX

John G Ullman & Associates Inc. decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 85.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,125 shares of the medical instruments supplier’s stock after selling 25,233 shares during the period. John G Ullman & Associates Inc.’s holdings in Becton, Dickinson and Company were worth $711,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Northcape Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after purchasing an additional 51 shares during the last quarter. Diversified Trust Co grew its stake in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 53 shares during the last quarter. Bill Few Associates Inc. grew its stake in shares of Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the last quarter. Horizon Bancorp Inc. IN lifted its holdings in Becton, Dickinson and Company by 10.9% in the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 56 shares during the period. Finally, Meadow Creek Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 5.4% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after buying an additional 59 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $189.20 on Friday. The firm’s 50-day moving average price is $190.60 and its 200-day moving average price is $184.63. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The firm has a market capitalization of $54.23 billion, a P/E ratio of 34.03, a P/E/G ratio of 1.48 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler restated a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 1,838 shares of company stock worth $348,392 over the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.